Today: 19 July 2026
Browse Category

NYSE:BMY 30 October 2025 - 23 December 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3
20 December 2025
········
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma
16 December 2025
···
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences, Inc. is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior session, reflecting investor repricing after Arcus and partner Gilead halted a pivotal upper-GI cancer study. StockAnalysis
14 December 2025
···
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Dec. 12, 2025 — Bristol-Myers Squibb Company is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and frustrating setbacks in 2025. By mid-day Friday, BMY stock traded around $52.50, up roughly 2.5% , reflecting a market that's starting to re-price near-term catalysts even as longer-term questions—patent cliffs, trial readouts, and litigation—remain front and center.
12 December 2025
·
Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb has packed a lot into the first week of December 2025 – from a surprise update on a key Alzheimer’s drug trial to major hematology data at ASH 2025 and a legal setback over its Celgene acquisition. All of this is landing on a stock that has finally bounced after years of underperformance but still trades as a high‑yield value name.
7 December 2025
·
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven R&D milestones, and fresh analyst calls. StockAnalysis
3 December 2025
····
Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb spent Saturday, November 29, 2025 out of the trading spotlight—U.S. markets were closed—but very much in the headlines. A cluster of fresh reports focused on three themes: a fat 5.4% dividend yield, big institutional investors quietly adding to their positions, and a Wall Street analyst community that largely refuses to move beyond a “Hold” stance on the stock. Nasdaq+2MarketBeat+2
30 November 2025
··
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030, €1.15B 2033, €1.15B 2038, €750M 2045, and €1.2B 2055 — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. Bristol Myers Squibb News
9 November 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 Marketbeat. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector Nasdaq. By comparison, an index of large pharmaceutical stocks was up modestly, making BMY one of 2025’s laggards.
30 October 2025
··
1 2 3
Go toTop